Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Carlyle Credit Solutions reported total investment income of $66.7 million for the quarter ended September 30, 2026, and net investment income of $38.3 million. Total net assets decreased slightly to $1.74 billion from $1.77 billion at year-end 2025, primarily driven by $51.7 million in net unrealized depreciation on investments and $129.7 million in distributions to stockholders.
AmperCap Acquisition Co's 10-Q filing for the period ending September 30, 2026, reflects its status as a blank check company with no current operations. The report details administrative expenses and interest income generated from the trust account as the company continues to evaluate potential business combination targets. No definitive merger agreements or significant changes in financial guidance were disclosed.
TRex Bio reported financial results for the third quarter of 2026, highlighting a net loss of $14.1 million and a cash position of $154.2 million. The company recently completed a $133.5 million IPO in October 2026, which extends its expected cash runway into the second half of 2029 to support its clinical pipeline, including TRB-061 and TRB-071.
Term
Q3 2026
“The positive Phase 1a results for TRB-061 demonstrated selective activation and expansion of immunoregulatory Tregs in humans, providing clinical evidence that we believe supports this approach. We are now focused on understanding whether these effects can translate into meaningful and durable disease control for patients with atopic dermatitis.”
Johnston Erwin, Chief Executive Officer of TRexBio
“With the completion of our IPO, we have the resources to advance TRB-061 toward its planned mid-2027 clinical readout and expect to bring TRB-071, which targets a distinct Treg pathway, into the clinic in the first half of 2027.”
Johnston Erwin, Chief Executive Officer of TRexBio
IRulya Therapeutics Inc. significantly strengthened its liquidity position in the first nine months of 2026, with cash and short-term investments increasing to $105.2 million from $17.8 million at year-end 2025. The company underwent a major restructuring of its balance sheet, eliminating over $100 million in total liabilities and issuing Series C Preferred Stock valued at $143.8 million following the acquisition of Orphai Therapeutics.
Propanc Biopharma reported a net loss of $8.6 million for the quarter ended September 30, 2026, compared to a $4.8 million loss in the prior year, driven largely by a significant increase in compensation and professional expenses. The company's cash position decreased to $258,366 from $832,006 at the start of the fiscal year, though it raised $2 million through the exercise of Series C warrants.
Air Industries Group reported a significant turnaround in the third quarter of 2026, with net sales increasing to $14.6 million and net income reaching $946,000 compared to a loss in the prior year period. However, for the nine months ended September 30, 2026, the company still recorded a net loss of $920,000 despite a 8.7% increase in year-to-date net sales.
Siebert Financial Corp. reported a net loss of $3.0 million for the nine months ended September 30, 2026, compared to a net income of $5.6 million in the prior year period. While total revenue grew to $79.3 million, expenses surged to $83.7 million, driven by higher employee compensation, technology costs, and one-time settlement and impairment charges.
SilverBox Corp IV reported a net income of $3.64 million for the nine months ended September 30, 2026, primarily driven by $4.77 million in interest earned on trust account investments. During the period, the company experienced significant redemptions, with $207.5 million withdrawn from the Trust Account, leaving $10.64 million in investments remaining.
BioKey (Cayman), Inc. reported zero revenue for the nine months ended September 30, 2026, with a net loss of $873,721 compared to $538,188 in the prior year period. The company remains heavily dependent on recurring loans from ABVC BioPharma, Inc. to support its operations, with total liabilities reaching $7.56 million against total assets of $1.61 million.
Arrive AI Inc. reported a net loss of $24.1 million for the nine months ended September 30, 2026, compared to a $10.1 million loss in the prior year period, driven largely by a $12.3 million loss on the conversion of notes. Total assets decreased to $9.2 million from $10.9 million at year-end 2025, while the company maintained a stockholders' equity of $2.2 million.
Planet Green Holdings Corp. reported a significant increase in net revenues to $9.58 million for the nine months ended September 30, 2026, compared to $67,270 in the prior year, though it still incurred a net loss of $1.04 million. The company's balance sheet shows a total stockholders' deficit of $3.06 million, and it continues to manage significant liabilities from discontinued operations.
CCS IX Portfolio Holdings, LLC reported a significant increase in total investment income to $58.6 million for the nine months ended September 30, 2026, compared to $18.5 million in the prior year period. Net assets grew to $732.4 million, driven by $353.3 million in capital contributions and $31.6 million in net increase in net assets from operations.
Dyadic International reported a net loss of $5.4 million for the nine months ended September 30, 2026, compared to $5.8 million in the prior year. The company is undergoing a strategic rebranding to Dyadic Applied BioSolutions, shifting focus from research to commercialized protein production platforms across life sciences and food sectors.
Saga Communications reported a net loss of $7.1 million for the third quarter of 2026, primarily driven by a $9.2 million impairment of intangible assets. Net operating revenue decreased to $26.7 million from $28.2 million in the prior year period, while total assets declined to $183.0 million as of September 30, 2026.
Waterstone Financial, Inc. reported net income of $20.6 million for the nine months ended September 30, 2026, an increase from $18.7 million in the prior year period. The company experienced a decrease in total assets to $2.25 billion, primarily driven by a reduction in loans held for sale and cash equivalents, while net interest income improved due to lower interest expenses on deposits and borrowings.
Spectral Capital Corporation reported a significant revenue increase to $865.9 million for the nine months ended September 30, 2026, compared to $3.1 million in the prior year, primarily driven by business combinations. Despite the revenue growth, the company realized a net loss of $5.4 million for the period due to high cost of revenues and increased operating expenses.
PMGC Holdings Inc. reported a significant revenue increase to $4.52 million for the nine months ended September 30, 2026, compared to $0.29 million in the prior year. However, net loss widened to $10.15 million due to increased operating expenses and interest costs, while the company underwent a series of reverse stock splits totaling 1-for-240.
Waterstone Financial reported Q3 2026 net income of $6.2 million, or $0.36 per diluted share, down from $7.9 million in the prior year quarter. The Community Banking segment achieved record quarterly net interest income of $16.0 million, while the Mortgage Banking segment faced a pre-tax loss of $754,000 due to rising mortgage rates and compressed sales margins.
Term
Q3 2026
“We are pleased with the hard work to reach another strong quarter with increased challenges from rising short-term and long-term treasury rates. The Community Banking segment realized another record quarterly net interest income of $16.0 million, which represented a $1.4 million increase compared to the quarter ended September 30, 2025.”
William Bruss, Chief Executive Officer of Waterstone Financial, Inc.
Actuate Therapeutics reported a net loss of $13.9 million for the nine months ended September 30, 2026, compared to $17.7 million in the prior year period. The company's cash position decreased significantly to $2.1 million, resulting in a working capital deficit and a stated going concern uncertainty as it continues to fund clinical development of elraglusib.
Stemtech Corp reported a significant decline in net sales to $1.37 million for the nine months ended September 30, 2026, compared to $2.42 million in the prior year period. The company continues to operate at a loss, with a net loss of $1.93 million for the first nine months of 2026 and a total stockholders' deficit of $8.38 million.
EXOZYMES INC. reported a net loss of $7.49 million for the nine months ended September 30, 2026, compared to a $6.50 million loss in the prior year. The company remains in a development stage with no operating income, primarily funded by a public offering and registered direct offering that raised approximately $5.86 million in net proceeds during the period.
BIO-key International reported total revenues of $5.5M for the nine months ended September 30, 2026, an increase from $4.9M in the prior year period, driven by higher license fees. Despite the revenue growth, the company incurred a net loss available to common stockholders of $6.2M, significantly impacted by a $4.5M deemed dividend related to a warrant inducement.
Santander Holdings USA, Inc. reported 530,391,043 shares of common stock outstanding as of October 31, 2026. The filing highlights significant strategic developments, including the acquisition of Webster and the subsequent merger of Webster Bank into SBNA, while noting risks related to inflation, interest rate volatility, and regulatory compliance.
Profusa, Inc. reported a net loss of $17.2 million for the nine months ended September 30, 2026, an improvement from the $31.2 million loss in the prior year period. The company's balance sheet was significantly impacted by the issuance of a $28.3 million G3 call option asset and the settlement of various liabilities through the issuance of Series A non-voting convertible preferred stock.
Amplify Commodity Trust reported a significant increase in combined net assets from $45.1 million at June 30, 2026, to $226.6 million at September 30, 2026, primarily driven by growth in the Breakwave Tanker Shipping ETF. The Tanker Shipping ETF saw its net asset value per share rise from $151.05 to $792.20 during the quarter, supported by $35.4 million in unrealized appreciation on futures contracts.
American Shared Hospital Services reported a net loss of $2,866,000 for the nine months ended September 30, 2026, compared to a loss of $1,719,000 in the prior year period. While total revenues increased to $23,138,000, higher operating costs and selling and administrative expenses led to an increased operating loss of $2,598,000.
For the nine months ended September 30, 2026, Utah Medical Products reported net sales of $25.87 million, a decrease from $29.48 million in the prior year period. Despite the decline in revenue, the company maintained profitability with a net income of $8.08 million and ended the period with a strong cash and investment balance of $85.20 million.
Green Planet Bio Engineering Co. Ltd. remains a shell company with no revenue and a net loss of $25,289 for the nine months ended September 30, 2026. The company's operations are funded through related party advances, resulting in a total stockholders' deficit of $526,265.
American Fusion, Inc. reported a net loss of $2.8 million for the nine months ended September 30, 2026, primarily driven by $2.7 million in operating expenses following its reverse recapitalization with Kepler Fusion Technologies. The company generated minimal revenue of $58,000 during the period and maintains a stockholders' deficit of $1.1 million.
StepStone Private Credit Fund LLC reported a significant increase in total investment income to $269.5 million for the nine months ended September 30, 2026, compared to $163.3 million in the prior year period. Net assets grew to $3.16 billion, driven by $1.32 billion in share issuances, although the net asset value per share slightly decreased from $26.03 to $25.81 during the period.